Tsung-Che Wu (@TsungCheWu) profile picture

Medical oncologist @ NTUH in Taiwan, phase 1, GI cancer, HCC, BTC, ESCC, CRC, lung cancer Tsung-Che (Nathan) Wu

Taipei City, Taiwan
Joined December 2013
Photo by Tsung-Che Wu (@TsungCheWu)Photo by Tsung-Che Wu (@TsungCheWu)Photo by Tsung-Che Wu (@TsungCheWu)Photo by Tsung-Che Wu (@TsungCheWu)
RT @hongjaechon: 💡 Does curative therapy after PR to Ate/Bev improve outcomes in uHCC? @ResearchKarger #LiverCancer 👉 vs PR without curati…
1
4
Great news! One subgroup I’ll be watching closely is patients with CLDN18.2 expression high enough for CLARITY-Gastric01 but below the zolbetuximab threshold. I’m also curious whether the KM curves and subsequent therapies can explain the OS benefit despite a negative PFS result. #myESMO @OncoAlert @oncodaily @OncoDailyGI @Larvol #GIOncology
Excited to see the positive results from Phase 3 CLARITY-Gastric 01. AZD0901, an anti-CLDN18.2 ADC, improved OS vs 2nd or later-line chemo in patients with CLDN18.2+ gastric/GEJ cancer. Please stay tuned for more details. @ESMO @AstraZeneca @OncoAlert astrazeneca.com/media-centre…
1
1
512
7-year PFS of 55% with lorlatinib is truly remarkable—arguably a new benchmark for targeted therapy in solid tumors. Other solid-tumor benchmarks across modalities include: Cytotoxic chemotherapy: BEP in testicular cancer — 5-year PFS ~90% in good-risk and 40~50% in poor-risk disease ADC: Trastuzumab deruxtecan in HER2+ breast cancer — 2L median PFS ~29 months Immunotherapy: Nivolumab + ipilimumab in dMMR/MSI-H mCRC — 4-year PFS ~65% Together, these examples remind us that with precise patient selection and continued optimization of existing drug modalities, transformative long-term disease control is still achievable in solid tumors. #ASCO26 @ASCO @OncoAlert @oncodaily
This PFS curve 🤯🤯🤯🤯🤯🤯🤯
5
1
13
1,911
Newest #ASCO26 example: NEXUS-01. Post-EV urothelial carcinoma treated with LY4052031 — anti–Nectin-4 ADC, TOP1i payload — showed encouraging activity, ORR ~33%. Another signal for the ADC sequencing rule: Same target, different payload → opportunity Different target, same payload → limited help Payload resistance may be the key. By the same logic, given the current dominance of TROP2–TOP1i ADCs, emerging TROP2–MMAE strategies such as LCB84 (NCT05941507) may be worth watching. @ASCO @OncoAlert @oncodaily #ADC
ADC sequencing is entering a new phase. At ESMO BC 2026, two prospective datasets raised an important caution: 1️⃣ SATEEN: trastuzumab + sacituzumab govitecan after prior T-DXd in HER2+ MBC ORR: 3.7% — only 1/27 confirmed response 2️⃣ HER3-DXd after prior TOP1-ADC exposure, including T-DXd, Dato-DXd and/or SG ORR: ~5% in both HR+/HER2– breast cancer and TNBC cohorts Different targets, similar TOP1 payload backbone — and very limited activity. These data strongly suggest that in many patients, ADC resistance may be driven more by payload-associated resistance than by antigen selection alone. This also fits the opposite clinical observation: when the payload changes, activity can still be meaningful — for example, T-DXd after T-DM1, or FRα-TOP1 ADC strategies after mirvetuximab soravtansine in ovarian cancer. The ADC field is still heavily concentrated around two payload classes: • TOP1 inhibitors • anti-microtubule agents Soon, many chemo-sensitive cancers may have one TOP1-based ADC and one microtubule-based ADC, often with the earlier-line ADC combined with anti-PD-1/PD-L1. That may already improve survival substantially. But to unlock the next level of benefit, we need more diversified ADC payloads — especially payloads that induce immunogenic cell death or other mechanisms that synergize with immunotherapy. @myESMO @oncodaily @OncoAlert
1
3
364
A warmup before ASCO: The rapid pace of oncology innovation is completely outstripping trial design. With the major NEJM publication of the HERIZON-GEA-01 trial, a new Standard of Care (SOC) emerges: Zanidatamab + tislelizumab + chemo wins in the ITT population, regardless of PD-L1 status.nejm.org/doi/full/10.1056/NE… But this creates a fascinating clinical & regulatory bottleneck: 🔹 ToGA (Trastuzumab + Chemo) was the benchmark for a decade. 🔹 KEYNOTE-811 advanced the needle but primarily for the PD-L1+ subgroup. 🔹 HERIZON-GEA-01 splits the 1L landscape wide open. Now, ongoing trials like ARTEMIDE-Gastric01 and DESTINY-Gastric05 are using KEYNOTE-811 as their control arms. How will we cross-compare them to a Zanidatamab-based triplet? And what about future branches from HERIZON-GEA-01? As our "treatment tree" (figure generated by GEMINI) sprouts new branches at an unprecedented speed, selecting the right 1L SOC (and subsequent 2L sequence) becomes highly fragmented. This same phenomenon is playing out in EGFRm NSCLC (MARIPOSA vs. FLAURA-2). Advancing the field? Absolutely. Navigating it? It's going to take collective wisdom from investigators, pharma, and regulatory agencies. #OncoTwitter @OncoDailyGI @oncodaily #GIonc #DrugDevelopment
🤖 Made with AI
1
1
4
283
Tsung-Che Wu retweeted
I have been so impressed by the recent Daraxonrasib data that I forgot the 25 year anniversary of the precision medicine OG - STI571 (Gleevec). What a triumph of modern medicine. And congratulations to @MelDMann - still going strong all these years later! npr.org/2026/05/10/nx-s1-577…
6
28
1
128
10,181
ADC sequencing is entering a new phase. At ESMO BC 2026, two prospective datasets raised an important caution: 1️⃣ SATEEN: trastuzumab + sacituzumab govitecan after prior T-DXd in HER2+ MBC ORR: 3.7% — only 1/27 confirmed response 2️⃣ HER3-DXd after prior TOP1-ADC exposure, including T-DXd, Dato-DXd and/or SG ORR: ~5% in both HR+/HER2– breast cancer and TNBC cohorts Different targets, similar TOP1 payload backbone — and very limited activity. These data strongly suggest that in many patients, ADC resistance may be driven more by payload-associated resistance than by antigen selection alone. This also fits the opposite clinical observation: when the payload changes, activity can still be meaningful — for example, T-DXd after T-DM1, or FRα-TOP1 ADC strategies after mirvetuximab soravtansine in ovarian cancer. The ADC field is still heavily concentrated around two payload classes: • TOP1 inhibitors • anti-microtubule agents Soon, many chemo-sensitive cancers may have one TOP1-based ADC and one microtubule-based ADC, often with the earlier-line ADC combined with anti-PD-1/PD-L1. That may already improve survival substantially. But to unlock the next level of benefit, we need more diversified ADC payloads — especially payloads that induce immunogenic cell death or other mechanisms that synergize with immunotherapy. @myESMO @oncodaily @OncoAlert
1
3
650
Promising next-generation CYPA-complex RAS inhibitor RM-055 is coming. It appears to overcome daraxonrasib resistance while showing better selectivity over WT RAS. But it also seems G12X-specific, raising an important question: will secondary non-G12X RAS mutations emerge as a resistance mechanism, and will combination with a pan-RAS inhibitor be needed to prevent or delay this? #AACR26 @RevMedicines @KRASKickers
New compound from @RevMedicines RM-055 disclosed at #AACR26 They took a subtle finding 👉🏽Daraxonrasib-CYPA complex modestly increasing RAS GTP hydrolysis 👉🏽 to build a RAS GAP on steroids. RM-055 flattens Daraxonrasib resistant tumors including RAS amplified cases across models.
1
2
10
2,776
A striking coincidence to have had RVMD present at the 12th A-TOPIC (Asia Oncology Phase I Trials Conference) yesterday. Daraxonrasib vs chemotherapy in 2L PDAC: OS 13.2 vs 6.7 months HR 0.40, p<0.0001 A PARADIGM SHIFT. This may represent the biggest advance in oncology since anti-PD-1 therapy, and perhaps the greatest improvement ever seen in GI oncology. This could create substantial opportunities for combination strategies: chemotherapy, allele-specific RAS inhibitors, PRMT5 inhibitors, anti-EGFR/other RTK-directed agents, and future p53 reactivators, with possible movement into adjuvant/neoadjuvant settings. Also watching with interest the clinical-stage tri-complex inhibitors ERAS-0015, BPI-572270, and GFH276. Will tri-complex inhibitors and newer SIIP inhibitors with ON-state activity show non-overlapping resistance patterns? @myESMO @oncoalert #oncotwitter #PDAC
3
6
1,207
Malaysian early phase researcher Dr Voon Pei Jye (Sarawak General Hospital) continue to make waves by taking the stage this weekend at the 12th Asia Oncology Phase 1 Trials Conference (A-TOPIC) in Taiwan. The conference gathers early phase researchers within the region, sharing insights of innovative drug developments in cancer.
2
7
345
DLL3 in GEP-NENs: new therapeutic window 🔥 High DLL3 expression: 71% GEP-NECs, 40% G3 NETs, esp. PanNET G3 (43%) ⚠️ DLL3+ G3 PanNETs → worse survival (HR 3.27) 🧪 DLL3-immunoPET detected avid lesions in 5/6 patients 💡DLL3: promising target for NEC & high-grade PanNETs 🔗 doi.org/10.1200/PO-25-00724
7
15
1,106
The @IASLC MCSC & ART has just published the practical approach for unresctable LA-NSCLC in @JTOonline! We provides 5 cases representing challenging scenarios for multidisciplinary discussion, inspiring best care for thoracic tumor boards. Read more 👉 tinyurl.com/4ux88xnh
1
6
14
1,054
Tsung-Che Wu retweeted
SKYSCRAPER-07: Phase III study of atezo with or without tiragolumab in unresectable ESCC that has not progressed following dCRT #ESMO25 #ESMOAmbassadors 👉 mPFS: 29 vs 20.8 vs 16.6 👉 mOS: n.r. vs 38 vs 36 mo 🧐Atezo improves outcome, but adding tiragolumab to atezo with detrimental effect @myesmo
3
20
48
4,791
IMvigor011: Adjuvant atezolizumab for MIBC patients with postoperative ctDNA+ → Positive for DFS & OS.natera.com/company/news/imvi… A fightback after IMvigor010 all-comer approach. Given NIAGARA & positive EV303 (and highly anticipated EV304), adjuvant atezo may not be mainstream—yet highlights potential adaptive strategies, e.g. de-escalation after neoadjuvant if ctDNA–. In solid tumors, MRD-guided treatment warrants pan-cancer exploration! #BladderCancer #MIBC #ctDNA #MRD #Immunotherapy #Atezolizumab #Oncology #CancerResearch #GUonc #ClinicalTrials @myESMO @OncoAlert
3
4
966
Catching up with old and new friends in HK! 🇭🇰🇦🇺🇲🇾🇸🇬🇮🇳🇹🇼🇰🇷 … over some delicious food, of course! Brought together thanks to #ESMOTATAsia25. Grateful to @RashidLui & Gerry Kwok for hosting us in their home town. @drdaviddwlee @EvelynWongYT @myESMO
1
2
13
981
Practice changing study for gastric cancer MATTERHORN: perioperative FLOT + Durvalumab vs FLOT + placebo nejm.org/doi/full/10.1056/NE… Primary endpoint: EFS- 2Y rate 67.4 vs 58.5%, HR 0.71, p<0.001 early OS trend: 2Y rate 75.1 vs 70.4% (Piecewise HR suggests widening separation ) @OncoAlert #asco25 #GIOnc #GastricCancer #immunotherapy @NEJM @Larvol Hope for more cures The practice pattern may shift from adjuvant to perioperative in east Asia
2
116
ASCENT04 changes practice w/ improved mPFS 11.2 vs. 7.8 mos; 12 mon PFS 48 vs 33 mos w/ impressive tail suggesting potential for group with durable sustained response; adverse events were not additive. Bonus points for cross over design. #ASCO25 @stolaney1 @OncoAlert
2
50
5
116
17,000